论文部分内容阅读
目的:观察康艾注射液对肝脏转移癌患者生活质量的影响。方法:将43例患者随机分为治疗组23例和对照组20例。治疗组用康艾注射液加支持疗法治疗,对照组采用单纯支持疗法治疗。观察karnofsky评分制(KPS)评分、疼痛分度法(VAs评分法)评分、体重及外周血象、胃肠道症状、静脉炎及心、肾功能变化等情况。结果:KPS评分改善率治疗组明显高于对照组。差异有显著性意义(P<0.05)。疼痛缓解率治疗组高于对照组,差异有显著性意义(P<0.05)。体重增加率治疗组也明显高于对照组,差异有显著性意义(P<0.05)。结论:康艾注射液可在一定程度上改善生活质量,延长生存期,并且无明显的毒副作用。值得临床推广使用。
Objective: To observe the effect of Kangai Injection on quality of life in patients with metastatic liver cancer. Methods: 43 patients were randomly divided into treatment group 23 cases and control group 20 cases. The treatment group with Kang AI injection and supportive therapy, the control group was treated with simple supportive therapy. Karnofsky score system (KPS) score, pain score (VAs score) score, body weight and peripheral blood, gastrointestinal symptoms, phlebitis and heart and kidney function changes were observed. Results: The KPS score improvement rate in the treatment group was significantly higher than that in the control group. The difference was significant (P <0.05). The pain relief rate was higher in the treatment group than in the control group, with significant difference (P <0.05). Weight gain rate in the treatment group was also significantly higher than the control group, the difference was significant (P <0.05). CONCLUSION: Kangai injection can improve the quality of life to a certain extent, prolong the survival period and have no obvious side effects. It is worth to promote clinical use.